Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.
2.

Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF.

Yamamoto N, Suyama H, Nakazato H, Yamamoto N, Koga Y.

Cancer Immunol Immunother. 2008 Jul;57(7):1007-16. Retraction in: Cancer Immunol Immunother. 2014 Dec;63(12):1349.

PMID:
18058096
3.
4.

Immunotherapy of HIV-infected patients with Gc protein-derived macrophage activating factor (GcMAF).

Yamamoto N, Ushijima N, Koga Y.

J Med Virol. 2009 Jan;81(1):16-26. doi: 10.1002/jmv.21376. Retraction in: J Med Virol. 2014 Nov;86(11):1998.

PMID:
19031451
5.

Antitumor effect of vitamin D-binding protein-derived macrophage activating factor on Ehrlich ascites tumor-bearing mice.

Koga Y, Naraparaju VR, Yamamoto N.

Proc Soc Exp Biol Med. 1999 Jan;220(1):20-6.

PMID:
9893164
7.

Structural modification of serum vitamin D3-binding protein and immunosuppression in AIDS patients.

Yamamoto N, Naraparaju VR, Srinivasula SM.

AIDS Res Hum Retroviruses. 1995 Nov;11(11):1373-8.

PMID:
8573395
8.

Tumor cell alpha-N-acetylgalactosaminidase activity and its involvement in GcMAF-related macrophage activation.

Mohamad SB, Nagasawa H, Uto Y, Hori H.

Comp Biochem Physiol A Mol Integr Physiol. 2002 May;132(1):1-8.

PMID:
12062184
10.
11.

Deglycosylation of serum vitamin D3-binding protein leads to immunosuppression in cancer patients.

Yamamoto N, Naraparaju VR, Asbell SO.

Cancer Res. 1996 Jun 15;56(12):2827-31.

12.
13.

GC protein-derived macrophage-activating factor decreases α-N-acetylgalactosaminidase levels in advanced cancer patients.

Thyer L, Ward E, Smith R, Branca JJ, Morucci G, Gulisano M, Noakes D, Eslinger R, Pacini S.

Oncoimmunology. 2013 Aug 1;2(8):e25769. Epub 2013 Jul 29.

14.
15.

Pathogenic significance of alpha-N-acetylgalactosaminidase activity found in the hemagglutinin of influenza virus.

Yamamoto N, Urade M.

Microbes Infect. 2005 Apr;7(4):674-81. Epub 2005 Mar 22.

PMID:
15848273
16.

β-Galactosidase treatment is a common first-stage modification of the three major subtypes of Gc protein to GcMAF.

Uto Y, Yamamoto S, Mukai H, Ishiyama N, Takeuchi R, Nakagawa Y, Hirota K, Terada H, Onizuka S, Hori H.

Anticancer Res. 2012 Jun;32(6):2359-64.

PMID:
22641675
18.

The Effect of Fucoidan from the Brown Alga Fucus evanescence on the Activity of α-N-Acetylgalactosaminidase of Human Colon Carcinoma Cells.

Bakunina I, Chadova O, Malyarenko O, Ermakova S.

Mar Drugs. 2018 May 10;16(5). pii: E155. doi: 10.3390/md16050155.

19.

Effect of the Gc-derived macrophage-activating factor precursor (preGcMAF) on phagocytic activation of mouse peritoneal macrophages.

Uto Y, Yamamoto S, Takeuchi R, Nakagawa Y, Hirota K, Terada H, Onizuka S, Nakata E, Hori H.

Anticancer Res. 2011 Jul;31(7):2489-92.

PMID:
21873164
20.

Gc protein-derived macrophage activating factor (GcMAF): isoelectric focusing pattern and tumoricidal activity.

Mohamad SB, Nagasawa H, Sasaki H, Uto Y, Nakagawa Y, Kawashima K, Hori H.

Anticancer Res. 2003 Nov-Dec;23(6a):4451-7.

PMID:
14666733

Supplemental Content

Support Center